Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-21 20:28:12 UTC |
---|
Update Date | 2014-12-24 20:25:54 UTC |
---|
Accession Number | T3D2963 |
---|
Identification |
---|
Common Name | Ethinamate |
---|
Class | Small Molecule |
---|
Description | Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia. Regular use leads to tolerance, and it is usually not effective for more than 7 days. Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates. |
---|
Compound Type | - Amine
- Carbamate
- Drug
- Ester
- Ether
- Hypnotic and Sedative
- Metabolite
- Organic Compound
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | 1-Ethynylcyclohexanol carbamate | Aethinyl-cyclohexyl-carbamat | Ethinamat | Ethinamatum | Ethinamic acid | Ethinimate | Etinamate | Etinamato | USAF EL-42 | Valamin | Valmid |
|
---|
Chemical Formula | C9H13NO2 |
---|
Average Molecular Mass | 167.205 g/mol |
---|
Monoisotopic Mass | 167.095 g/mol |
---|
CAS Registry Number | 126-52-3 |
---|
IUPAC Name | 1-ethynylcyclohexyl carbamate |
---|
Traditional Name | ethinamate |
---|
SMILES | OC(=N)OC1(CCCCC1)C#C |
---|
InChI Identifier | InChI=1S/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11) |
---|
InChI Key | InChIKey=GXRZIMHKGDIBEW-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as ynones. These are organic compounds containing the ynone functional group, an alpha,beta unsaturated ketone group with the general structure RC#C-C(=O)R' (R' not H). |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic oxygen compounds |
---|
Class | Organooxygen compounds |
---|
Sub Class | Carbonyl compounds |
---|
Direct Parent | Ynones |
---|
Alternative Parents | |
---|
Substituents | - Ynone
- Carbamic acid ester
- Carbonic acid derivative
- Acetylide
- Organic nitrogen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organonitrogen compound
- Aliphatic homomonocyclic compound
|
---|
Molecular Framework | Aliphatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 94-96°C | Boiling Point | 120°C at 3.00E+00 mm Hg | Solubility | 2500 mg/L (at 25°C) | LogP | 1.2 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-054o-9000000000-115ca538c5db7623cd36 | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - CI-B (Non-derivatized) | splash10-004i-0900000000-3530aac44af3672b4ea8 | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-054o-9000000000-115ca538c5db7623cd36 | 2018-05-18 | View Spectrum | GC-MS | GC-MS Spectrum - CI-B (Non-derivatized) | splash10-004i-0900000000-3530aac44af3672b4ea8 | 2018-05-18 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-052f-9400000000-b2399bc8d370f3c24953 | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-016r-1900000000-eae16bf8bad39a8aa79b | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-056r-4900000000-5017ae578b8cb02cd66d | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0ktf-9100000000-cd1eedbdd6d6fcbfa22e | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-006x-9800000000-e408920834450f49d3fe | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-006x-9500000000-877c16eefea2f5a15d9b | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0006-9300000000-b9a9228e0ee207499b99 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0a4i-2900000000-10552185ed182d4ba1e0 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0a4i-9700000000-cd8eef43ebf47b3d3b7b | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-004i-9100000000-9313282cbda800790a68 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0avl-2900000000-d0731a549bbc943d745e | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0006-9500000000-35acbd59dd232e271712 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0006-9000000000-ff48c45d4a47d2073ba7 | 2021-10-11 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0arv-9100000000-713c62aa52e71fc3560a | 2014-09-20 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Rapidly absorbed following oral administration. |
---|
Mechanism of Toxicity | The mechanism of action is not known. However, studies have shown that ethinamate inhibits carbonic anhydrases I and II (J Biol Chem. 1992 Dec 15;267(35):25044-50). This inhibition by ethinamate is not sufficiently strong, however, to implicate carbonic anhydrases I and II in the mechanism of action. |
---|
Metabolism | Hepatic.
Half Life: 2.5 hours |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | Used for the short-term treatment of insomnia, however, it generally has been replaced by other sedative-hypnotic agents. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. |
---|
Symptoms | Symptoms of overdose include shortness of breath or slow or troubled breathing, slow heartbeat, severe weakness, chronic confusion, slurred speech, and staggering. |
---|
Treatment | Not Available |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB01031 |
---|
HMDB ID | HMDB15165 |
---|
PubChem Compound ID | 3284 |
---|
ChEMBL ID | CHEMBL1576 |
---|
ChemSpider ID | 3169 |
---|
KEGG ID | C07832 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 4884 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Ethinamate |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Ethinamate |
---|
References |
---|
Synthesis Reference | Junkmann, K. and Pfeiffer, H.; US. Patent 2,816,910; December 17, 1957; assigned to
Schering AG, Germany. |
---|
MSDS | Not Available |
---|
General References | - Drugs.com [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|